Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo

Investigative Ophthalmology and Visual Science

Volumn 46, Issue 5, 2005, Pages 1647-1652

  Singhb, Nirbhai ^a   Amin, Shivan ^a   Richter, Elizabeth ^a   Rashid, Saadia ^a   Scoglietti, Vincent ^a   Jani, Pooja D ^a   Wang, Jin ^a   Kaur, Rajwinder ^a   Ambati, Jayakrishna ^b   Dong, Zheng ^a   Ambati, Balamurali K ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN SUBUNIT; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; FLT1 PROTEIN, HUMAN; FLT1 PROTEIN, MOUSE; FLTN PROTEIN, MOUSE; KDEL RECEPTOR; PROTEIN; RECEPTOR; SCLEROPROTEIN; VASCULOTROPIN A;

ANGIOGENESIS; ARTICLE; CONTROLLED STUDY; CORNEA EPITHELIUM; CORNEA INJURY; CORNEA NEOVASCULARIZATION; DRUG EFFECT; ENDOPLASMIC RETICULUM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HYPOXEMIA; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE COUNT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANOXIA; CELL LINE; DRUG COMBINATION; GENE VECTOR; GENETIC TRANSFECTION; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; PLASMID; WESTERN BLOTTING;

ANIMALS; ANOXIA; BLOTTING, WESTERN; CELL LINE; CORNEAL NEOVASCULARIZATION; DRUG COMBINATIONS; ENDOPLASMIC RETICULUM; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIUM, CORNEAL; EXTRACELLULAR MATRIX PROTEINS; GENETIC VECTORS; LEUKOCYTE COUNT; MICE; PLASMIDS; PROTEINS; RECEPTORS, PEPTIDE; TRANSFECTION; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 20444482034     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.04-1172     Document Type: Article

References (51)

1. Epstein RJ, Stulting RD, Hendricks, RL, et al. Corneal neovascularization. Cornea. 1987;6:250-257.
2. Amano S, Rohan R, Kuroki M, et al. Requirement for VEGF in wound- and inflammation-induced neovascularization. Invest Ophthalmol Vis Sci. 1998;39:18-22.
3. Carmeliet P, Collen D. Role of vascular endothelial growth factor and vascular endothelial growth factor receptors in vascular development. Curr Top Microbiol Immunol. 1999;237:133-158.
4. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol. 1999;237: 97-132.
5. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med. 1995;1: 1024-1028.
6. Kong HL, Hecht D, Song W, et al. Regional suppression of tumor growth by secreted flt-1. Hum Gene Ther. 1998;9:823-833.
7. Abu-Jawdeh GM, Faix JD, Niloff J, et al. Strong expression of VEGF in ovarian neoplasms. Lab Invest. 1996;74:1105-1115.
8. Ambati J, Chalam KV, Chawla DK, et al. Elevated GABA, glutamate, and VEGF in vitreous of patients with PDR. Arch Ophthalmol. 1997;115:1161-1166.
9. Boocock CA, Charnock-Jones DS, Sharkey A, et al. Expression of VEGF in ovarian carcinoma. J Natl Cancer Inst. 1995;87:506-516.
10. Doldi N, Bassan M, Gulisano M, et al. VEGF mRNA in human ovarian and endometrial cancer. Gynecol Endocrinol. 1996;10: 375-382.
11. Pierce EA, Avery RL, Foley ED, et al. VEGF expression in a mouse model of retinal neovascularization. Proc Natl Acad Sd USA. 1995;92:905-909.
12. Miller JW, Adamis AP, Shima DT, et al. VEGF is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol. 1994;145:574-584.
13. Neufeld G, Cohen T, Gengrinovitch S, et al. VEGF and its receptors. FASEB J. 1999;13:9-22.
14. Millauer B, Wizigmann-Voos S, Schnurch H, et al. High affinity VEGF binding and developmental expression suggest FLK-1 as a major regulator of vasculogenesis and angiogenesis. Cell. 1993;72: 835-846.
15. Waltenberger J, Claesson-Welsh L, Siegbahn A, et al. Different signal transduction properties of KDR and FLT. J Biol Chem. 1994;269:26988-26995.
16. Shibuya M. Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). Intl J Biochem Cell Biol. 2001; 33:409-420.
17. Wiesmann C, Fuh G, Christinger HW, et al. Crystal structure at 1.7 angstroms resolution of VEGF in complex with domain 2 of the Flt-1 receptor. Cell. 1997;91:695-704.
18. Barleon B, Totzke F, Herzog C, et al. Mapping for the sites of ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor Flt-1. J Biol Chem. 1997; 272:10382-10388.
19. Kim KJ, Li B, Winer J, et al. Inhibition of VEGF-induced angiogenesis suppresses tumor growth in vivo. Nature. 1993;362:841-844.
20. Yuan F, Chen Y, Dellian M, et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by anti-VEGF antibody. Proc Natl Acad Sci USA. 1996;93:14765-14770.
21. Lin P, Sankar S, Shan S, et al. Inhibition of tumor growth by targeting tumor endothelium using a soluble VEGF receptor. Cell Growth Differ. 1998;9:49-58.
22. Hasan J, Jayson GC. VEGF antagonists. Expert Opin Biol Ther. 2001;1:703-718.
23. Robinson GS, Pierce EA, Rook SL, et al. Oligonucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA. 1996;93:4851-4856.
24. Aiello LP, Pierce EA, Foley EA, et al. Suppression of retinal neovascularization in vivo by inhibition of VEGF using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA. 1995;92: 10457-10461.
25. Honda M, Sakamoto T, Ishibashi T, et al. Experimental subretinal neovascularization is inhibited by sFLT. Gene Ther. 2000;7:978-985.
26. Lai YKY, Sjen WY, Brankov M, et al. Potential long-term inhibition of ocular neovascularization by recombinant AAV-mediated gene therapy. Gene Ther. 2002;2002:804-813.
27. Lee YH, Tokunaga T, Oshika Y, et al. Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma. Eur J Cancer. 1999;35:1089-1093.
28. Masood R, Cai J, Zheng T, et al. VEGF is an autocrine growth factor for VEGF receptor-positive human tumors. Blood. 2001;98:1904-1913.
29. Shen BQ, Lee DY, Gerber HP, et al. Homologous upregulation of VEGFR-2 by VEGF. J Biol Chem. 1998;273:29979-29985.
30. Shih IM, Herlyn M. Autocrine and paracrine roles for growth factors in melanoma. In Vivo. 1994;8:113-123.
31. Bellamy WT, Richter L, Sirjani D, et al. VEGF is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplasia. Blood. 2001;97: 1427-1434.
32. Casella I, Feccia T, Chelucci C, et al. Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor. Blood. 2003;101:1316-1323.
33. Fiedler W, Graeven U, Ergun S, et al. VEGF in human AML. Blood. 1997;89:1870-1875.
34. Straume O, Akslen LA. Expression of VEGF, its receptors and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol. 2001;159:223-235.
35. Liu W, Ellis WM. Regulation of KDR by a soluble factor in confluent endothelial cells. Pathobiology. 1998;66:247-252.
36. Gerber HP, Mallk AK, Solar GP, et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature. 2002;417:954-958.
37. Pelham HR. The retention signal for soluble proteins of the endoplasmic reticulum. Trends Biochem Sci. 1990;15:483-486.
38. Chen J, Bai X, Yang A, et al. Inactivation of chemokine co-receptor CXCR-4 by a novel intrakine strategy. Nat Med. 1997;3:1110-1116.
39. Kreitman RJ, Puri RK, Pastan I. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human cancer. Cancer Res. 1995;55:3357-3363.
40. Luis Abad J, Gonzalez MA, del Real G, et al. Novel interfering bifunctional molecules against the CCR5 coreceptor are efficient inhibitors of HIV-1 infection. Mol Ther. 2003;8:475-484.
41. Steinberger P, Andris-Widhopf J, Buhler B, et al. Functional deletion of CCR5 by intracellular immunization produces cells refractory to CCR5-dependent HIV-1 infection and cell fusion. Proc Natl Acad Sci. 2000;97:805-810.
42. Usui T, Ishida S, Yamashiro K, et al. VEGF 164(165) as the pathological isoform: differential leukocyte responses. Invest Ophthalmol Vis Sci. 2004;45:368-374.
43. Gan L, Fagerholm P. Leukocytes in early events of corneal neovascularization. Cornea. 2001;20:96-99.
44. Becker MD, Kruse FE, Azzam L, et al. In vivo significance of ICAM-1 dependent leukocyte adhesion in early corneal angiogenesis. Invest Ophthalmol Vis Sci. 1999;40:612-618.
45. Namiki A, Brogi E, Kearney M, et al. Hypoxia induces VEGF in cultured human endothelial cells. J Biol Chem. 1995;270:31189-31195.
46. Nomura M, Yamagishi S, Harada S, et al. Possible participation of autocrine and paracrine VEGF in hypoxia-induced proliferation of endothelial cells and pericytes. J Biol Chem. 1995;270:28316-28324.
47. Ambati BK, Joussen AM, Anand A, et al. Angiostatin inhibits and regresses corneal neovascularization. Arch Ophthalmol. 2002;120: 1063-1068.
48. Ambati BK, Anand A, Joussen AM, et al. Sustained inhibition of corneal neovascularization by genetic ablation of CCR5. Invest Ophthalmol Vis Sci. 2003;44:590-593.
49. Ambati BK, Joussen AM, Kuziel WA, et al. Inhibition of corneal neovascularization by genetic ablation of CCR2. Cornea. 2003;22: 465-467.
50. Stechschulte SU, Joussen AM, von Recum HA, et al. Rapid ocular angiogenic control via naked DNA delivery to cornea. Invest Ophthalmol Vis Sci. 2001;42:1975-1979.
51. Proia AD, Chandler DB, Haynes WL, et al. Quantitation of corneal neovascularization using computerized image analysis. Lab Invest. 1988;58:473-479.